Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia

OBJECTIVE: Anamorelin, a novel selective ghrelin receptor agonist, was approved in Japan for the treatment of cachexia in pancreatic cancer (PC), albeit with limited evidence. This study evaluated the efficacy and safety of anamorelin in PC and examined the impact of the extent of weight loss on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Tsuyoshi, Sasaki, Takashi, Okamoto, Takeshi, Ishitsuka, Takahiro, Yamada, Manabu, Nakagawa, Hiroki, Mie, Takafumi, Furukawa, Takaaki, Kasuga, Akiyoshi, Matsuyama, Masato, Ozaka, Masato, Sasahira, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372274/
https://www.ncbi.nlm.nih.gov/pubmed/36418096
http://dx.doi.org/10.2169/internalmedicine.0730-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372274/
https://www.ncbi.nlm.nih.gov/pubmed/36418096
http://dx.doi.org/10.2169/internalmedicine.0730-22

Ejemplares similares